The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review

References

• Multiple Sclerosis International Federation [Internet]. Atlas of MS; 2013; [cited 2016 Mar 8]. Available from: https://www.msif.org/about-us/advocacy/atlas/
   Google Scholar
• MS Australia. Understanding Multiple Sclerosis: types; 2015; [cited 2015 May 3]. Available from: http://www.msaustralia.org.au/understanding-ms/what-is-ms/types
   Google Scholar
• Kelleher KJ, Spence W, Solomonidis S, et al. The characterisation of gait patterns of people with multiple sclerosis. Disabil Rehabil. 2010;32:1242–1250.
   PubMed Web of Science ®Google Scholar
• Mutch K. Information for young people when multiple sclerosis enters the family. Br J Nurs. 2005;14:758–760.
   PubMedGoogle Scholar
• Australian Bureau of Statistics. Multiple Sclerosis; 2009; [cited 2015 May 3]. Available from: http://www.abs.gov.au/ausstats/[email protected]/Lookup/4429.0Main+Features100182009
   Google Scholar
• Crenshaw SJ, Royer TD, Richards JG, et al. Gait variability in people with multiple sclerosis. Mult Scler. 2006;12:613–619.
   PubMed Web of Science ®Google Scholar
• Doring A, Pfueller CF, Paul F, et al. Exercise in multiple sclerosis – an integral component of disease management. EPMA J. 2011;3:2.
   PubMedGoogle Scholar
• Yamout B, Alroughani R, Al-Jumah M, et al. Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Curr Med Res Opin. 2013;29:611–621.
   PubMed Web of Science ®Google Scholar
• Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chron Dis. 2013;4:192–205.
   PubMedGoogle Scholar
• Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68:494–502.
   PubMed Web of Science ®Google Scholar
• Orsnes GB, Sorensen PS, Larsen TK, et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand. 2000;101:244–248.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517–1526.
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451–459.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Multiple Scler. 2007;13:357–368.
   PubMed Web of Science ®Google Scholar
• Solari A, Uitdehaag Bernard MJ, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev. 2001;4:CD001330.
   Google Scholar
• Jensen HB, Ravnborg M, Dalgas U, et al. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7:97–113.
   PubMed Web of Science ®Google Scholar
• OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence; 2011; [cited 2015 Dec 15]. Available from: http://www.cebm.net/index.aspx?o=5653
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Physiotherapy Evidence Database. PEDro scale; 1999; [cited 2015 May 21]. Available from: http://www.pedro.org.au/english/downloads/pedro-scale/
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. 2009;339:b2700.
   Google Scholar
• Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Can Med Assoc J. 2012;184:1143–1150.
   PubMed Web of Science ®Google Scholar
• Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997;48:817–821.
   PubMed Web of Science ®Google Scholar
• Jensen HB, Nielsen JL, Ravnborg M, et al. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Multiple Scler Relat Disord. 2016;10:137–144.
   PubMed Web of Science ®Google Scholar
• Zorner B, Filli L, Reuter K, et al. Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Multiple Scler. 2016;22:1463–1475.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71:1134–1141.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732–738.
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex) as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122–1131.
   PubMed Web of Science ®Google Scholar
• Yapundich R, Applebee A, Bethoux F, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: a randomized controlled trial. Int J MS Care. 2015;17:138–145.
   PubMedGoogle Scholar
• Baert I, Freeman J, Smedal T, et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis. A European Multicenter Study. Neurorehabil Neural Repair. 2014;28:621–631.
   PubMed Web of Science ®Google Scholar
• Learmonth YC, Dlugonski DD, Pilutti LA, et al. The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis. Multiple Scler. 2013;19:1784–1791.
   PubMed Web of Science ®Google Scholar
• Musselman KE. Clinical significance testing in rehabilitation research: what, why, and how? Phys Ther Rev. 2007;12:287–296.
   Google Scholar
• Perera S, Mody SH, Woodman RC, et al. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54:743–749.
   PubMed Web of Science ®Google Scholar
• van Loo MA, Moseley AM, Bosman JM, et al. Test–re-test reliability of walking speed, step length and step width measurement after traumatic brain injury: a pilot study. Brain Injury. 2004;18:1041–1048.
   PubMed Web of Science ®Google Scholar
• Perry J, Garrett M, Gronley JK, et al. Classification of walking handicap in the stroke population. Stroke. 1995;26:982–989.
   PubMed Web of Science ®Google Scholar
• Salbach NM, O'Brien K, Brooks D, et al. Speed and distance requirements for community ambulation: a systematic review. Arch Phys Med Rehabil. 2014;95:117–128.e11.
   PubMed Web of Science ®Google Scholar
• Kirtley C, Whittle MW, Jefferson RJ. Influence of walking speed on gait parameters. J Biomed Eng. 1985;7:282–288.
   PubMedGoogle Scholar
• Plummer P. Critical appraisal of evidence for improving gait speed in people with multiple sclerosis: dalfampridine versus gait training. Int J MS Care. 2016;18:105–115.
   PubMedGoogle Scholar